June 2020

As pharma companies around the world race to develop a viable treatment for Covid-19, a number of therapeutic candidates have emerged as potential solutions. One of the most promising drugs currently being trialled is Remdesivir, an antiviral medication originally developed by Gilead Sciences to treat Ebola. We take a look at the current state of Remdesivir and other Covid-19 candidates to find out more about the race to find a cure.

Also in the next issue, we investigate ongoing backlash against Aspirin and ibuprofen, find out if a sophisticated laboratory model of the human body could help practitioners to detect harmful or adverse effects of drugs before they are prescribed to patients, and delve into the complex subject of drug pricing to see if crisis situations should change the way that regulators approach the issue.

Plus, we take a look at the next wave of anticoagulants, examine ViiV Healthcare and UNC-Chapel Hill’s “induce and reduce” approach to eliminating HIV, investigate what the Veeva vs IQVIA anti-competitive lawsuit means for pharma data issues and ownership, and find out if nanoparticles are the solution to unlocking the pharma benefits of turmeric.


Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor | Daniel Garrun

Writers | Allie Nawrat, Chloe Kent, Abi Millar 
Magazine Designer | Marzia Del Gaone

Graphic Designers | Filipe Costa, Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Martina Labaiova
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West


Sales Manager | Nimai Amin

+44 (0) 207 936 6453


For media partnership enquiries please contact our publishing assistant: Sophie Hoare

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.